Du sparer 0% ift. normalprisen Spar 0%

Hardback
8-11 hverdage
1.330,95 kr.

Bag om Antibody-Drug Conjugates

Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg (R)), Brentuximab vedotin (Adcetris (R)), and ado-trastuzumab emtansine (Kadcyla (R)), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011).

Vis mere

Sprog:
Engelsk

ISBN:
9783319130804

Forlag:
Springer International Publishing AG

Indbinding:
Hardback

Sideantal:
252

Udgivet:
6. marts 2015

Udgave:
2015

Størrelse:
246x164x19 mm.

Vægt:
552 g.

Leveringstid: 8-11 hverdage.
Forventet levering: 5. december 2024

På lager

Normalpris

BLACK NOVEMBER
1.330,95 kr. + Fragt
~~1.330,95 kr.~~

Medlemspris

1.280,95 kr.

Prøv i 30 dage for 45 kr.
Herefter fra 79 kr./md. Ingen binding.

Beskrivelse af Antibody-Drug Conjugates

Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg (R)), Brentuximab vedotin (Adcetris (R)), and ado-trastuzumab emtansine (Kadcyla (R)), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011).

Brugerbedømmelser af Antibody-Drug Conjugates

Andre købte også..

Find lignende bøger

Bogen Antibody-Drug Conjugates findes i følgende kategorier:

Business og læring

Antibody-Drug Conjugates - Bog

Beskrivelse af Antibody-Drug Conjugates

Brugerbedømmelser af Antibody-Drug Conjugates

Gør som tusindvis af andre bogelskere